CTCF and neoplasm: Clinical translation could be accelerated through biomarker-guided cohort stratification in immunotherapy trials, coupled with exploration of small-molecule inhibitors targeting hypoxia-induced CTCF stabilization to disrupt Neu2-mediated tumor progression.